Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
Goutzamanis S, Doyle J, Higgs P, Hellard M Disease Elimination Program, Burnet Institute.
Share
Abstract
With approximately 71 million people chronically infected worldwide and 1.75 million new infections in 2015, hepatitis C virus remains a significant public health concern. In developed countries hepatitis C transmission is predominantly driven by the sharing of injecting equipment, placing people who inject drugs (PWID) at the greatest risk of infection. It is estimated that approximately half of the PWID population are hepatitis C antibody positive. This article is protected by copyright. All rights reserved.
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present. We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
Oops!
It looks like something may have gone wrong, and some of the resources required to load the page may not have loaded correctly.
